PhRMA Feels Deadline Pressure, Reminds FDA Of Flexibility In PDUFA Goals
Executive Summary
The Pharmaceutical Research & Manufacturers of America is suggesting that FDA can miss its user fee deadline for a product if prolonging the review would lead to swifter approval than entering a second cycle
You may also be interested in...
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
PDUFA IV Negotiations Underway With FDA, Industry Working In Harmony
PhRMA will pursue earlier postmarketing commitment negotiations with FDA as part of a limited industry agenda for the third reauthorization of the Prescription Drug User Fee Act
Phase IV Discussions Should Begin Earlier In Review Process, Wyeth Says
Wyeth wants FDA to direct reviewers to initiate Phase IV discussions with sponsors several weeks before a user fee action date